Oxprenolol


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
AV block (2nd and 3rd degree), bradycardia, uncontrolled heart failure, hypotension, history of bronchospasm or bronchial asthma, sick sinus syndrome, cardiogenic shock, severe peripheral arterial circulatory disturbances, Prinzmetal's angina, metabolic acidosis and use of anaesth.
Special Precautions
Chronic obstructive lung disease, 1st degree AV block, untreated CHF, peripheral vascular disease (e.g. Raynaud's syndrome). May mask symptoms of hypoglycaemia and hyperthyroidism. Hepatic and renal impairment. Abrupt withdrawal of treatment is not advisable in patients w/ ischaemic heart disease. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery.
Adverse Reactions
Hypotension, heart failure, peripheral vascular disorders (e.g. cold extremities, paraesthesia). Fatigue, dizziness, headache, mental depression, disturbances in libido and potency. Dry mouth, constipation, nausea, dyspnoea, bronchoconstriction, skin rash.
Drug Interactions
May enhance effects of insulin and oral antidiabetics. Concurrent use w/ cimetidine may increase plasma levels and prolong half-life. May enhance the vasoconstrictive effects of ergot alkaloids. Potentiation of hypotension, bradycardia and myocardial depression may occur w/ Ca channel blockers (e.g. diltiazem, verapamil). May have additive cardiodepressant effect w/ anaesth (e.g. halothane). Enhanced pressor response to sympathomimetic drugs (e.g. epinephrine, phenylephrine, isoprenaline, noradrenaline). Concomitant admin w/ quinidine, amiodarone, disopyramide may induce negative inotropic effect and increase atrial-conduction time. May enhance lidocaine effects. Additive effect w/ reserpine, guanethidine. May enhance depressant effect w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.
CIMS Class
ATC Classification
C07AA02 - oxprenolol ; Belongs to the class of non-selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on oxprenolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in